Send to

Choose Destination
Reprod Toxicol. 2019 Jan;83:14-20. doi: 10.1016/j.reprotox.2018.10.010. Epub 2018 Oct 29.

First trimester ondansetron exposure and risk of structural birth defects.

Author information

TTi Health Research & Economics, 1231 Tech Ct, Suite 201, Westminster, MD 21157, USA. Electronic address:
TTi Health Research & Economics, 1231 Tech Ct, Suite 201, Westminster, MD 21157, USA.
Department of Community and Family Health, College of Public Health, University of South Florida, 13201 Bruce B Downs Blvd, Tampa, FL 33612, USA.


This study investigates risk of specific structural birth defects associated with ondansetron exposure during the first trimester in a large US commercially-insured population. Medical claims data were obtained from Truven Health Analytics for 864,083 mother-infant pairs from 2000 to 2014. Logistic regression was used to measure the association between first trimester exposure to ondansetron and risk of cardiac defects, orofacial clefts and other specific structural defects in offspring. First trimester exposure to ondansetron was associated with increased risk of cardiac (OR: 1.52 95% CI: 1.35-1.70) and orofacial cleft defects (OR: 1.32 95% CI: 0.76-2.28) in offspring compared to women with no antiemetic exposure during pregnancy. This analysis addresses limitations of prior studies including limited power, exposure misclassification, and generalizability to the US population. In a large, US population we found a statistically significant association between early pregnancy ondansetron exposure and specific structural birth defects in offspring.


Birth defects; Cardiac defects; Congenital anomalies; Congenital malformations; Nausea and vomiting in pregnancy; Ondansetron; Orofacial clefts; Zofran

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center